263 related articles for article (PubMed ID: 28771673)
1. Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Hagner PR; Chiu H; Ortiz M; Apollonio B; Wang M; Couto S; Waldman MF; Flynt E; Ramsay AG; Trotter M; Gandhi AK; Chopra R; Thakurta A
Br J Haematol; 2017 Nov; 179(3):399-409. PubMed ID: 28771673
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
3. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
5. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Wang M; Schuster SJ; Phillips T; Lossos IS; Goy A; Rule S; Hamadani M; Ghosh N; Reeder CB; Barnett E; Bravo MC; Martin P
J Hematol Oncol; 2017 Nov; 10(1):171. PubMed ID: 29096668
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.
Gribben JG; Fowler N; Morschhauser F
J Clin Oncol; 2015 Sep; 33(25):2803-11. PubMed ID: 26195701
[TBL] [Abstract][Full Text] [Related]
7. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Arcaini L; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Cabeçadas J; Campo E; Pileri SA; Biyukov T; Patturajan M; Casadebaig Bravo ML; Trnĕný M;
Br J Haematol; 2018 Jan; 180(2):224-235. PubMed ID: 29193019
[TBL] [Abstract][Full Text] [Related]
8. Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis.
Ma J; Wu K; Bai W; Cui X; Chen Y; Xie Y; Xie Y
EBioMedicine; 2017 Jun; 20():70-78. PubMed ID: 28529032
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.
Zhang L; Qian Z; Cai Z; Sun L; Wang H; Bartlett JB; Yi Q; Wang M
Am J Hematol; 2009 Sep; 84(9):553-9. PubMed ID: 19565649
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
[TBL] [Abstract][Full Text] [Related]
11. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide for the treatment of B-cell lymphoma.
Garciaz S; Coso D; Schiano de Colella JM; Bouabdallah R
Expert Opin Investig Drugs; 2016 Sep; 25(9):1103-16. PubMed ID: 27414850
[TBL] [Abstract][Full Text] [Related]
14. Treatment options for mantle cell lymphoma.
Smolewski P; Witkowska M; Robak T
Expert Opin Pharmacother; 2015; 16(16):2497-507. PubMed ID: 26360791
[TBL] [Abstract][Full Text] [Related]
15. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Wu C; de Miranda NF; Chen L; Wasik AM; Mansouri L; Jurczak W; Galazka K; Dlugosz-Danecka M; Machaczka M; Zhang H; Peng R; Morin RD; Rosenquist R; Sander B; Pan-Hammarström Q
Oncotarget; 2016 Jun; 7(25):38180-38190. PubMed ID: 27224912
[TBL] [Abstract][Full Text] [Related]
16. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.
Vidal-Crespo A; Rodriguez V; Matas-Cespedes A; Lee E; Rivas-Delgado A; Giné E; Navarro A; Beà S; Campo E; López-Guillermo A; Lopez-Guerra M; Roué G; Colomer D; Pérez-Galán P
Haematologica; 2017 Nov; 102(11):e447-e451. PubMed ID: 28838994
[No Abstract] [Full Text] [Related]
17. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Kritharis A; Coyle M; Sharma J; Evens AM
Blood; 2015 Apr; 125(16):2471-6. PubMed ID: 25736312
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide for mantle cell lymphoma.
Skarbnik AP; Goy AH
Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Zinzani PL; Vose JM; Czuczman MS; Reeder CB; Haioun C; Polikoff J; Tilly H; Zhang L; Prandi K; Li J; Witzig TE
Ann Oncol; 2013 Nov; 24(11):2892-7. PubMed ID: 24030098
[TBL] [Abstract][Full Text] [Related]
20. Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
Chiu H; Trisal P; Bjorklund C; Carrancio S; Toraño EG; Guarinos C; Papazoglou D; Hagner PR; Beldi-Ferchiou A; Tarte K; Delfau-Larue MH; Morschhauser F; Ramsay AG; Gandhi AK
Br J Haematol; 2019 Apr; 185(2):240-253. PubMed ID: 30767211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
